Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a special supplement boost health in cystic fibrosis?

NCT ID NCT07163078

Disease control Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 21, 2026 · Updated 3 times

Summary

This study will test whether a nutrition supplement with different forms of certain nutrients works better than standard supplements for adults with cystic fibrosis. Sixty participants will take the supplement for six weeks, and researchers will measure nutrient levels in their blood before and after. The goal is to see if the new formula improves how the body absorbs and uses key vitamins and minerals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nutrition supplement with common and uncommon nutrients
What this could lead to
If it works, this could point toward a better way to manage nutrient deficiencies in cystic fibrosis.
What could go wrong
This is a small, early-stage study with only 60 people. It only measures blood markers, not long-term health outcomes, so results may not lead to a clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with cystic fibrosis * Diagnosed with exocrine pancreatic insufficiency * 18 years old or older * Currently on modulator * Normal liver enzyme labs Exclusion Criteria: : * Non-English-speaking participants * Acute health crisis * Persistent elevation of liver enzymes \>6 months (E2) (ALT \>80 U/L) * History of liver abnormalities * If patients are currently taking Category A or Category B in the LiverTox categorization system * Recent vitamin D supplementation of 30 mcg/day or higher, vitamin E supplements of 200 IU/day or higher, or copper at 2 mg/day or higher * Any other concern by investigator that the subject is inappropriate for inclusion * Patients who is on a reduced dose of a CFTR modulator * Patients on azole antifungals (voriconazole, itraconazole, posaconzole, \>7 days of fluconazole, etc.). * Patients who binge drink EtOH - for men more than 2 drinks/day, for women more than 1 drink/ day * Patients that are on other medications that are sensitive CYP3A4 substrates - such as tacrolimus for example * Patients on sensitive CYP3A4 substrates including but not limited to tacrolimus, sirolimus, and cyclosporine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cystic fibrosis (CF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cystic fibrosis exocrine pancreatic insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cystic fibrosis (CF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nationwide Children's Hospital-Ohio State University

    Columbus, Ohio, 43016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.